



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.,
H.No. 1-140, Rajeswari Ware House,
Opposite to Sri Convention, Kompally,
Quthbullapur, Hyderabad,
Rangachal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

To,
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy,
Towers, Dalal Street,
Fort, Mumbai - 400 001.

Date: 28.05.2022

Scrip code: 531015

Dear Sir/Madam,

Sub: Audited Financial Results for the Quarter and year ended 31st March, 2021:

Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on 12th May, 2022 had inter-alia,

- (i) Approved the Audited Financial Results of the Company for the quarter and year ended 31st March, 2021 and Auditors Report thereon.

This is for your information and record.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited

Nooka
Krishna
iah

N. Krishnaiah
Director
DIN:07279009





**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF QUARTERLY AND ANNUAL
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF VENMAX DRUGS AND PHARMACEUTICALS
LIMITED**

Opinion

We have audited the accompanying quarterly financial results of **VENMAX DRUGS AND PHARMACEUTICALS LIMITED** (the company) for the quarter ended 31st March, 2021 and the year to date results for the period from 1st April, 2020 to 31st March, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31st March, 2021 and the year to date results for the period from 1st April, 2020 to 31st March, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



NSVR & ASSOCIATES LLP

Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results for the quarter and year ended 31st March, 2021

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the company to express an opinion on the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

The statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under Listing Regulations.

For M/s. NSVR & ASSOCIATES LLP
Chartered Accountants
FRN: 008801S/S200060


Suresh Gannamani

Partner

M No. 226870

UDIN: 22226870ALVBIA9166



Place: Hyderabad

Date: 28/05/2022



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.
H.No. 1-140, Rajeswari Ware House,
Opposite to Sri Convention, Kompally,
Quthbullapur, Hyderabad,
Wardhal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

VENMAX DRUGS AND PHARMACEUTICALS LIMITED						
H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad Rangareddi TG 500055						
(CTN: L24236TG1988PLC009102)						
Rs.in Lakhs						
Audited Financial results for the Quarter and Year ended March, 2021						
S No	Particulars	Quarter Ended			Year ended	
		Quarter ended March 31, 2021	Quarter ended December 31, 2020	Quarter ended March 31, 2020	Year ended March 31, 2021	Year ended March 31, 2020
		Audited	Un Audited	Audited	Audited	Audited
1	Income					
	a) Revenue from Operations	-0.00	(0.00)	10.81	16.79	47.22
	Total Revenue from operations	-0.00	-0.00	10.81	16.79	47.22
	b) Other Income	18.14	-	0.00	18.14	0.08
	Total Income	18.14	-0.00	10.81	34.93	47.30
2	Expenses					
	Raw Material Consumed	-	-0.00	12.02	7.86	42.77
	Changes in inventories of work-in-progress	5.74	(0.00)	-6.45	21.58	(11.04)
	Employee benefits	1.20	1.50	8.88	6.27	21.65
	Finance cost	-0.00	0.00	0.04	-	-
	Depreciation	0.26	0.26	0.33	1.03	1.29
	Other expenses	8.88	1.40	7.53	14.37	19.35
	Total Expenses (a to g)	16.07	3.15	22.34	51.11	74.03
3	Profit before tax (1-2)	2.07	-3.15	-11.53	-16.18	-26.73
4	Tax expenses					
	- Income Tax	-	-	-	-	-
	- Deferred Tax	0.02	0.02	(0.05)	0.07	0.63
5	Net Profit for the period (3-4)	2.05	-3.17	-11.49	-16.25	-27.36
6	Other comprehensive income					
	a) (i) Items that will not be reclassified	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	b) (i) Items that will be reclassified to	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-
7	Total Comprehensive income (5 +6)	2.05	-3.17	-11.49	-16.25	-27.36
8	Paid-up Equity Share Capital (Rs.10/- per Equity Share)	523.89	523.89	523.89	523.89	523.89
9	Other Equity	-	-	-	-802.52	-786.28
10	Earnings per share (Face Value of Rs.10/- each) :					
	(a) Basic (in Rs.)	0.04	-0.06	-0.22	-0.31	-0.52
	(b) Diluted (in Rs.)	0.04	-0.06	-0.22	-0.31	-0.52
Notes						
a) The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016.						
b) The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 12.05.2022.						
c) The Statutory Auditors of the Company have carried out audit of the above audited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.						
d) The figures for the quarter ended March 31, 2021 and March 31, 2020 are balancing figures between the audited figures in respect of the full financial year and year to date figures upto the third quarter for the respective periods which were subject to limited review.						
e) The entire operations of the Company relate to only one segment. Hence segmental reporting as per Ind AS 108 is not made.						
f) The financials results for the year ended 31.03.2021 are also available on the Bombay stock exchange website and on the company's website.						
<div style="text-align: right;">For and on Behalf of Board of Directors</div> <div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div> Place: Hyderabad Date: 12-05-2022 </div> <div style="text-align: right;"> Raj Kumar Rai (Managing Director) DIN: 00009207 </div> </div>						

VENMAX DRUGS AND PHARMACEUTICALS LIMITED H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad (CIN: L24230TG1988PLC009102) Statement of Assets and Liabilities		
	Rs.In Lakhs	
Particulars	As at March 31, 2021 (Audited)	As at March 31, 2020 (Audited)
ASSETS		
Non-current Assets		
(a)Property, Plant and Equipment	6.21	6.95
(b)Investment Property	-	-
(c)Intangible Assets	2.81	3.11
(d)Financial Assets		
(i)Investments	-	-
(ii)Loans and Advances	-	-
(e)Deferred Tax Assets (Net)	-	-
(f)Other Non-current Assets	-	-
Total Non-current Assets	9.02	10.06
Current Assets		
(a)Inventories	-	21.58
(b)Financial Assets		
(i)Investments	-	-
(ii)Trade Receivables	3.62	3.80
(iii)Cash and Cash Equivalents	7.53	0.13
(iv)Bank Balances other than above (iii)	-	-
(v)Other Financial Assets	-	-
(c)Current Tax Assets (Net)	-	-
(d)Other Current Assets	10.58	10.02
Total Current Assets	21.73	35.53
Total Assets	30.75	45.59
Equity and Liabilities		
Equity		
(a)Equity Share Capital	523.89	523.89
(b)Other Equity	-801.50	-786.28
Total Equity	-277.60	-262.38
Liabilities		
Non-current Liabilities		
(a)Financial Liabilities		
(i)Long-term borrowings	-	-
(b)Provisions	-	-
(c)Deferred Tax Liabilities (Net)	0.42	0.36
Total Non-current Liabilities	0.42	0.36
Current liabilities		
(a)Financial Liabilities		
(i)Short-term borrowings	232.90	251.89
(ii)Trade payables - total dues of:		
:small and micro enterprises		
: others than small and micro enterprises	46.47	40.21
(iii)Other financial liabilities	19.51	13.11
(b)Other current liabilities	5.78	2.41
(c)Provisions	3.27	-
(d)Current Tax Liability (Net)	-	-
Total Current Liabilities	307.93	307.62
Total Liabilities	30.75	45.59



N. Krishnaiah
Director
(N KRISHNAIAH)

VENMAX DRUGS AND PHARMACEUTICALS LIMITED

H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad Rangareddi TG 500055

(CIN: L24230TG1988PLC009102)

Cash Flow statement for the period ended 31 March 2021

Particulars	For the year ended 31 March, 2021	For the year ended 31 March, 2020
A. Cash Flow from Operating Activities:		
Profit before tax for the year	-15.15	-26.73
Adjustments for:		
Depreciation	1.03	1.29
Finance Charges	-	-
Operating Profit before working capital changes	-14.12	-25.43
Adjustments for:		
(Increase) / Decrease in Inventory	21.58	-11.04
(Increase) / Decrease in Trade receivables	0.18	-3.58
(Increase) / Decrease in Current Financial assets	-	-
(Increase) / Decrease in Other Current assets	-0.56	0.51
(Decrease) / Increase in Trade payables	6.26	9.06
Increase / (Decrease in provisions)	3.27	1.05
(Decrease) / Increase in Other Current liabilities	3.37	-
(Decrease) / Increase in Other Financial liabilities	6.41	1.48
Cash Generated from Operations	26.39	-27.95
Taxes Paid (Net)	-	-
Net Cash (used) / from Operating Activities (A)	26.39	-27.95
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets including Capital Advances and Capital Creditors	-	-
Investments	-	-
Interest Received	-	-
Net Cash from / (used) Investing Activities (B)	-	-
C. Cash Flow from Financing Activities:		
Interest Paid	-	-
Receipt / (Repayment) of short term borrowings	-18.99	27.70
Net Cash from / (used) Financing Activities (C)	-18.99	27.70
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	7.39	-0.25
Cash and Cash equivalents at beginning of the year	0.13	0.38
Cash and Cash equivalents at end of the year	7.53	0.13

1) Cash and Cash equivalents includes:

Particulars	For the year ended 31 March, 2021	For the year ended 31 March, 2020
Cash on hand	7.52	0.00
Cash Equivalents		
- Current accounts	0.01	0.13
	7.53	0.13



For VENMAX DRUGS AND PHARMACEUTICALS LTD.

N. Krishnaiah

Director
(N KRISHNAIAH)



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Venmax Drugs and Pharmaceuticals Ltd.,
F.No. 1-140, Rajeswari Ware House,
Opposite to Sri Convention, Kompally,
Guthhullapur, Hyderabad,
Rangachal Dist-500014, Telangana.
E-mail: venmaxdrugs@gmail.com

Date: 28.05.2022

To,
BSE Limited,
Phiroze Jeejeebhoy,
Towers, Dalal Street,
Fort, Mumbai - 400001.

Scrip code: 531015

Dear Sir/Madam,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, N. Krishnaiah, Director of Venmax Drugs and Pharmaceuticals Limited hereby declare that, the statutory Auditors of the company, M/s. NSVR & Associates LLP, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2021.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours faithfully,

For Venmax Drugs and Pharmaceuticals Limited

Nooka
Krishnaiah
(Digitally signed by
Nooka Krishnaiah
DN: cn=Nooka Krishnaiah,
o=VENMAX DRUGS AND PHARMACEUTICALS LTD.,
c=IN)

N. Krishnaiah
Director
DIN:07279009

